Jack Rogan

Jack Rogan began their career in 2016 as an Analytical Chemist at CK Science, where they were part of the CK Analytical Technologies team at Eli Lilly. Jack'srole involved analysis, method development, and purification of molecules through Supercritical Fluid Chromatography (SFC) and Reverse- and Normal-phase Liquid Chromatography (LC). In 2018, they joined STORM Therapeutics Limited as a Scientist (Mass Spectrometry). In this role, Jack developed and implemented methods and standard protocols for strategies to separate and analyse total RNA oligonucleotides and mononucleotides by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), as well as developing code tools in R to interpret and visualise the results. Jack also contributed to the ongoing effort to expand the field of RNA epigenetic drug discovery. Jack was later promoted to Associate Scientist (Mass spectrometry), where they continued to develop methods for strategies to separate and analyse total RNA and RNA oligonucleotides by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), as well as developing code tools in R to both interpret and visualise the results.

Jack Rogan completed their Masters in Chemistry from Imperial College London between 2010 and 2015.